T W Dunn1, J R Vittengl2, L A Clark3, T Carmody1, M E Thase4, R B Jarrett1. 1. The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. 2. Truman State University, Kirksville, MO, USA. 3. University of Iowa, Iowa City, IA, USA. 4. University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Major depressive disorder (MDD) is highly prevalent, is recurrent, and impairs people's work, relationships and leisure. Acute-phase treatments improve psychosocial impairment associated with MDD, but how these improvements occur is unclear. In this study, we tested the hypotheses that reductions in depressive symptoms exceed, precede and predict improvements in psychosocial functioning. METHOD: Patients with recurrent MDD (n=523; 68% women, 81% Caucasian, mean age 42 years) received acute-phase cognitive therapy (CT). We measured functioning and symptom severity with the Social Adjustment Scale - Self-Report (SAS-SR), Range of Impaired Functioning Tool (RIFT), Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAMD) and Inventory for Depressive Symptomatology - Self-Report (IDS-SR). We tested cross-lagged correlations between functioning and symptoms measured at baseline and the beginning, middle and end of acute-phase CT. RESULTS: Pre- to post-treatment improvement in psychosocial functioning and depressive symptoms was large and intercorrelated. Depressive symptoms improved more and sooner than did psychosocial functioning. However, among four assessments across the course of treatment, improvements in functioning more strongly predicted later improvement in symptoms than vice versa. CONCLUSIONS: Improvements in psychosocial functioning and depressive symptoms correlate substantially during acute-phase CT, and improvements in functioning may play a role in subsequent symptom reduction during acute-phase CT.
BACKGROUND:Major depressive disorder (MDD) is highly prevalent, is recurrent, and impairs people's work, relationships and leisure. Acute-phase treatments improve psychosocial impairment associated with MDD, but how these improvements occur is unclear. In this study, we tested the hypotheses that reductions in depressive symptoms exceed, precede and predict improvements in psychosocial functioning. METHOD:Patients with recurrent MDD (n=523; 68% women, 81% Caucasian, mean age 42 years) received acute-phase cognitive therapy (CT). We measured functioning and symptom severity with the Social Adjustment Scale - Self-Report (SAS-SR), Range of Impaired Functioning Tool (RIFT), Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAMD) and Inventory for Depressive Symptomatology - Self-Report (IDS-SR). We tested cross-lagged correlations between functioning and symptoms measured at baseline and the beginning, middle and end of acute-phase CT. RESULTS: Pre- to post-treatment improvement in psychosocial functioning and depressive symptoms was large and intercorrelated. Depressive symptoms improved more and sooner than did psychosocial functioning. However, among four assessments across the course of treatment, improvements in functioning more strongly predicted later improvement in symptoms than vice versa. CONCLUSIONS: Improvements in psychosocial functioning and depressive symptoms correlate substantially during acute-phase CT, and improvements in functioning may play a role in subsequent symptom reduction during acute-phase CT.
Authors: A John Rush; Helena C Kraemer; Harold A Sackeim; Maurizio Fava; Madhukar H Trivedi; Ellen Frank; Philip T Ninan; Michael E Thase; Alan J Gelenberg; David J Kupfer; Darrel A Regier; Jerrold F Rosenbaum; Oakley Ray; Alan F Schatzberg Journal: Neuropsychopharmacology Date: 2006-06-21 Impact factor: 7.853
Authors: Sona Dimidjian; Steven D Hollon; Keith S Dobson; Karen B Schmaling; Robert J Kohlenberg; Michael E Addis; Robert Gallop; Joseph B McGlinchey; David K Markley; Jackie K Gollan; David C Atkins; David L Dunner; Neil S Jacobson Journal: J Consult Clin Psychol Date: 2006-08
Authors: Steven D Hollon; Robert J DeRubeis; Richard C Shelton; Jay D Amsterdam; Ronald M Salomon; John P O'Reardon; Margaret L Lovett; Paula R Young; Kirsten L Haman; Brent B Freeman; Robert Gallop Journal: Arch Gen Psychiatry Date: 2005-04
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Joseph M Trombello; Jeffrey R Vittengl; Wayne H Denton; Abu Minhajuddin; Michael E Thase; Robin B Jarrett Journal: Behav Ther Date: 2018-12-06
Authors: Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: Jeffrey R Vittengl; Lee Anna Clark; Jasper A J Smits; Michael E Thase; Robin B Jarrett Journal: J Affect Disord Date: 2018-08-25 Impact factor: 4.839
Authors: Samantha Meltzer-Brody; Sarah E Bledsoe-Mansori; Nell Johnson; Candace Killian; Robert M Hamer; Christine Jackson; Julia Wessel; John Thorp Journal: Am J Obstet Gynecol Date: 2012-12-12 Impact factor: 8.661